This is a prospective, observational, multicenter registry designed to collect comprehensive clinical, genetic, and outcome data from patients diagnosed with amyotrophic lateral sclerosis (ALS) across Thailand. The registry will establish a national dataset to describe epidemiology, clinical presentation, progression, and treatment outcomes, and will serve as a platform for future clinical and translational research.
Amyotrophic lateral sclerosis (ALS) is a fatal neurodegenerative disorder that affects upper and lower motor neurons, leading to progressive muscle weakness, disability, and respiratory failure. Despite increasing research worldwide, Thailand lacks large-scale systematic data on ALS epidemiology, clinical characteristics, genetic profiles, and outcomes. This registry will prospectively enroll ALS patients from major academic hospitals and specialized neuromuscular centers nationwide. Patients will be followed longitudinally using standardized assessments, including ALSFRS-R, staging systems (King, MiTos, 9-point), motor and respiratory function, quality-of-life measures, and cognitive/behavioral evaluations. Data will be collected through a REDCap electronic database, ensuring confidentiality and compliance with Thai PDPA and international data protection standards. No experimental interventions will be performed; patients will receive standard of care treatments as determined by their treating physicians.
Study Type
OBSERVATIONAL
Enrollment
100
King Chulalongkorn Memorial hospital, The Thai Red Cross Society
Pathum Wan, Bangkok, Thailand
RECRUITINGSurvival
Time Frame: From enrollment until death from any cause (assessed continuously, with updates at each follow-up). Outcome: Overall survival in ALS patients across Thailand, with survival curves stratified by demographic, clinical, and genetic factors.
Time frame: 10 years
ALS Functional Decline
Measure: Change in ALS Functional Rating Scale-Revised (ALSFRS-R) score. Time Frame: Every 6-12 months. Outcome: Rate of functional decline, expressed as points lost per month/year.
Time frame: 10 years
Disease Staging Progression
Measure: King's and MiToS staging systems, 9-point staging. Time Frame: Every 6-12 months. Outcome: Proportion of patients progressing to higher stages; median time to stage transitions.
Time frame: 10 years
Respiratory Outcomes
Measure: Forced vital capacity (FVC % predicted). Time Frame: Every 6-12 months. Outcome: Decline in FVC
Time frame: 10 years
Changes in health-related quality of life over time.
Measure: EQ-5D-5L. Time Frame: Annually. Outcome: Changes in health-related quality of life over time.
Time frame: 10 years
Cognitive and Behavioral Profile
Measure: Edinburgh Cognitive and Behavioral ALS Screen (ECAS) Time Frame: Annually. Outcome: Frequency and pattern of cognitive/behavioral impairment in ALS patients.
Time frame: 10 years
Genetic and Environmental Risk Associations
Measure: Frequency of ALS-associated genetic variants (e.g., SOD1, C9orf72, TARDBP, FUS) and correlation with clinical phenotype and progression. Time Frame: As available. Outcome: Genotype-phenotype correlation; association with disease onset, progression, and survival.
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: 10 years
Healthcare Utilization and Treatment Patterns
Measure: Use of riluzole, edaravone, non-invasive ventilation, gastrostomy, and multidisciplinary ALS clinic care. Time Frame: Throughout follow-up. Outcome: Patterns of treatment access and their association with survival and quality of life.
Time frame: 10 years